



New Antimicrobial Options in the Clinical Practice of Infections Caused by Difficult-to-Treat Pathogens: A Global Opportunity for Public Health

Guest Editor:

Dr. Luigi Principe

Microbiology and Virology Unit,
Great Metropolitan Hospital
"Bianchi-Melacrino-Morelli",
Reggio Calabria, Italy

Deadline for manuscript
submissions:

closed (31 January 2022)

Message from the Guest Editor

Dear Colleagues,

Antimicrobial resistance (AMR) is a serious cause of concern for public health. Difficult-to-treat pathogens are diffused worldwide, and related infections are associated to the important fatality rate. This Special Issue considers all aspects of infections related to difficult-to-treat pathogens and antimicrobial options. Articles or reviews regarding pan-drug- (PDR) or extensive drug-resistant (XDR) pathogens, metallo- β -lactamase (MBL)-producing Enterobacterales, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and vancomycin-resistant *Enterococcus* are encouraged.

Keywords: new antibiotics; new antimicrobial options; difficult-to-treat pathogens; emerging resistance; multidrug resistance; emerging virulence; *Acinetobacter baumannii*; *Pseudomonas aeruginosa*; metallo- β -lactamase-producing enterobacterales; vancomycin-resistant *Enterococcus*





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)